ENLV.TA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-0.08	$-0.08–$-0.08	—	1
2027	$0	—	$-0.09	$-0.09–$-0.09	—	1
2028	$0	—	$-0.93	$-0.93–$-0.93	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-03-25	$-0.27	$-0.45	-65.2%
2025-11-14	$-0.44	$-0.39	+11.4%
2025-08-29	$-0.49	$-0.38	+22.5%
2025-05-30	$-0.57	$-0.55	+3.3%
2025-03-31	$-0.58	$-0.57	+2.3%
2024-11-29	$-0.60	$-0.45	+23.9%
2024-08-19	$-0.57	$-0.57	+0.0%
2024-06-14	$-0.92	$-0.85	+8.0%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ENLV.TAEnlivex Therapeutics Ltd.	$269.70	+0.00%	$66M	—
BLRX.TABioLineRx Ltd.	$1.30	+0.00%	$34M	—
CANF.TACan-Fite BioPharma Ltd.	$348.90	-0.23%	$15M	—
CBI.TAClal Biotechnology Industries Ltd.	$24.70	+0.82%	$39M	—
EVGN.TAEvogene Ltd.	$158.10

Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company specializing in immunotherapy through macrophage reprogramming. The company's primary therapeutic candidate, Allocetra, is a cell-based treatment currently in a Phase II clinical trial for organ dysfunction and failure linked to sepsis. Allocetra is also being investigated in preclinical studies for its application against solid tumors. Furthermore, Enlivex has partnered with BeiGene to evaluate Allocetra's safety and efficacy when administered alongside tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for advanced solid tumor patients. The company's headquarters are located in Ness Ziona, Israel.

www.enlivex.com

Employees: 77
IPO / List date: Jul 22, 2019
HQ: IL

Held by traders on TradeandTell

No one on the platform currently holds ENLV.TA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ENLV.TA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ENLV.TA yet.